Connect with us

Technology

DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation

Published

on

This partnership has effectively integrated DP’s ADC Linker-Payload design platform with Lepu’s ADC technology development platform, capitalizing on their respective strengths. The overall optimization of the ADC drug has been achieved in a relatively short time.

BEIJING, Nov. 20, 2024 /PRNewswire/ — Lepu Biopharma Co., Ltd. (Lepu Biopharma) and Beijing DP Tech Co., Ltd. (DP Technology) have recently announced a significant milestone in their Antibody-Drug Conjugate (ADC) drug collaboration. This partnership has effectively integrated DP’s ADC Linker-Payload design platform with Lepu’s ADC technology development platform, capitalizing on their respective strengths. The overall optimization of the ADC drug has been achieved in a relatively short time. This project has reached an important milestone, further validating the approach of accelerating ADC innovative drug development through computational design. Moving forward, both parties will continue to deepen their R&D collaboration in this field, jointly committed to promoting the continuous optimization and advancement of innovative drug development processes.

The ADC Linker Payload design platform, meticulously crafted by DP Technology, utilizes “RiDYMO®”, an AI-for-Science driven hit discovery platform. Furthermore, “AI + first principles” based computational methods are employed to predict linker cleavage sites and ensure the correct payload release, achieving outstanding cell-killing and bystander effects. Additionally, the designed antibody-drug conjugates (ADCs) maintain excellent hydrophilicity and plasma stability. Leveraging Lepu’s mature and complete ADC development system, candidates developed by the new ADC platform have demonstrated significant efficacy in CDX models targeting multiple targets. This project has been successfully validated in animal models and is currently advancing the candidate ADC to the clinical stage.

Lei Fang, Ph.D., Vice President of Lepu Biopharma and CEO of CtM Bio Co., Ltd., expressed high appreciation for this cooperation: “Introducing advanced computational methods to solve scientific problems and jointly pioneering breakthrough explorations is our goal in the ADC project collaboration. As a leader in ‘AI for Science’, DP Technology has played a crucial role in this project with its newly developed ADC design platform. By integrating Lepu Biopharma’s advanced ADC development platform with AI-driven design, we proposed novel perspectives on ADC development while significantly expediting the process. By complementing each other’s strengths, we jointly provide new inspiration and ideas for innovative ADC drug design.”

Weijie Sun, CEO of DP Technology, expressed great anticipation for future collaboration: “Lepu Biopharma, as an innovative biopharmaceutical company focused on cancer treatment, particularly in the areas of targeted therapy and immunotherapy, has extensive experience and a long-standing track record in developing innovative ADC drugs. We firmly believe that our close cooperation will significantly accelerate the design and development of ADC drugs, and we are optimistic about the potential to develop innovative, highly effective, and differentiated new ADC therapies. I am eagerly anticipating the ongoing and deepened collaboration between both companies in the field of pharmaceutical innovation!”

Concerning the various demands from industry partners in the ADC field, DP Technology’s ADC platform has successfully empowered various scenarios and projects. For instance, it utilizes AI combined with first-principles calculations to predict linker cleavage sites and improve attachment stability. By integrating pre-trained models with fine-tuning strategies and expert insights, the platform can predict and modify physicochemical properties such as payload efflux and bystander effects. Additionally, there is ongoing exploration and collaboration in the overall evaluation of properties like aggregation effects in ADCs.

About Lepu Biopharma

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company focusing on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy, with a strong China foundation and global vision. We are dedicated to developing innovative ADCs through an advanced ADC technology development platform. We aim to develop more optimal and innovative drugs to better serve the unmet medical needs of cancer patients. We endeavor to continuously develop a market-differentiating pipeline by combining in-house research and development as well as strategic collaborations, strengthen our in-house manufacturing capabilities and commercialize our pipeline products in China through dedicated sales and marketing forces, and internationally via partnerships. We have an integrated end-to-end capability across drug discovery, clinical development, CMC and GMP-compliant manufacturing, encompassing critical functions of the biopharmaceutical value chain, and are building dedicated sales and marketing forces.

About DP Technology

At DP Technology, we’re at the forefront of integrating artificial intelligence into scientific research and industrial R&D. Our “AI for Science” initiative is redefining how we tackle complex scientific challenges, making groundbreaking discoveries more accessible and actionable.

We’ve developed the “DP Particle Universe,” a suite of advanced pre-trained models that seamlessly connect cutting-edge research with real-world industrial applications. Our software suite includes: Bohrium® Scientific Computing Space Station, Hermite® Computational Drug Design Platform, RiDYMO® Hit Discovery Platform, Piloteye® Battery Design Automation Platform. Together, these platforms form a robust foundation for industrial innovation and an open ecosystem for AI in science, fostering advancements in key areas such as drug discovery, energy, materials science and information technology.

View original content:https://www.prnewswire.com/news-releases/dp-technology-and-lepu-biopharma-announce-milestone-collaboration-leveraging-advanced-computational-methods-to-accelerate-adc-drug-innovation-302312430.html

SOURCE DP Technology

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Tow4Tech announces First-of-its-Kind Platform to Seamlessly Connect the Commercial Trucking Industry with Elite Tow Operators Nationwide

Published

on

By

Transforming dispatch services with a disruptive, multi sided, enterprise software solution

SAN FRANCISCO, Nov. 21, 2024 /PRNewswire/ — Tow4Tech, a pioneering technology company aiming to transform dispatching to the heavy-duty towing and roadside assistance industry, announces their innovative software platform, which streamlines the process of connecting commercial trucking companies and fleet managers with medium and heavy-duty tow operators and roadside assistance providers.

“We bring forward automation to a market that has long relied on inefficient workflow,” said Ziv Gillat, CTO of Tow4Tech. “By leveraging advanced technology and analysis with a deep understanding of the market needs, we developed a seamless and effective multi-pronged solution that benefits fleet managers and tow operators.”

Tow4Tech eliminates the inefficiencies and high costs associated with traditional call center operations for fleet managers. The platform’s geolocation technology automatically locates the nearest qualified tow operators, dispatches them, and manages all job details. By doing so, Tow4Tech optimizes the “Time to Tow” and minimizes downtime which enhances overall operational efficiency.

The company’s data analytics also provides crucial information for tracking business operations and optimizing performance. Furthermore, Tow4Tech offers a built-in payment system providing integrated invoicing and payment processing.

For tow operators and roadside assistance providers, Tow4Tech offers free exposure to job opportunities without the need for costly advertising. Operators receive exclusive medium and heavy-duty job dispatches directly to their devices, maintain full control over their rates, and keep 100% of their earnings. 

“By connecting fleet managers directly with top-tier tow operators, we’re creating a marketplace that is a win-win for both industries,” said Craig Schneider, CEO of Tow4Tech. “Our platform not only streamlines operations but also empowers service providers to maximize their earnings and efficiency. The time for innovation is now.”

Tow4Tech is attending the American Towman Exposition in Baltimore, Maryland, November 21-23. Please visit us at Booth 2116.

About Tow4Tech:

Tow4Tech is a pioneering technology company committed to modernizing the dispatching for heavy-duty towing and roadside assistance industry through innovative software solutions. By seamlessly connecting commercial trucking companies and fleet managers with elite medium and heavy-duty tow operators and roadside assistance providers nationwide, Tow4Tech integrates the capacity of providers while streamlining operations and reducing downtime. The company’s advanced platform eliminates the inefficiencies of traditional call centers by leveraging geolocation technology to automatically locate, dispatch, and manage towing and roadside assistance services. These towing and roadside assistance companies benefit from free exposure to job opportunities, maintaining full control over their rates and receiving 100% of their earnings. Tow4Tech is dedicated to enhancing operational efficiency, providing 24/7 customer support, and empowering both fleet managers and service providers with cutting-edge tools.

For more information, visit www.tow4tech.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tow4tech-announces-first-of-its-kind-platform-to-seamlessly-connect-the-commercial-trucking-industry-with-elite-tow-operators-nationwide-302312464.html

SOURCE Tow4Tech

Continue Reading

Technology

Workiz Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™

Published

on

By

The leading field service management solution attributes its significant revenue growth to its commitment to innovation, AI leadership, and a strong growth mindset.

SAN DIEGO, Nov. 21, 2024 /PRNewswire/ — Workiz, the leading field service management platform with over 120,000 customers, today announced it is now on the Deloitte Technology Fast 500™ list, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. Workiz experienced substantial growth during this period, helping its customers achieve an average revenue increase of 35% after their first year using the platform.

Workiz CEO Didi Azaria attributes the company’s impressive growth to its commitment to advancing the field service industry through cutting-edge AI and staying closely connected with service professionals.

“This recognition highlights the innovative, AI-driven solutions we’re bringing to the field service industry,” Azaria said. “Our growth reflects our customers’ success, helping them scale and expand their businesses, especially as they manage multi-location operations. We remain committed to supporting their evolving needs and driving their growth forward.”

As the leading field service management solution for both field service businesses with multiple locations and franchises, Workiz offers an array of tools to help service professionals streamline operations, improve customer satisfaction and scale their businesses. From job scheduling and dispatching to invoicing, payment tools, and AI-driven features like Genius, Workiz is setting the standard for innovation in the industry.

“Workiz has totally changed the way we run our business,” said John Batiste, owner of Grand Rapids Appliance Repair. “It’s easy to use and packed with great features that have helped us grow, work more efficiently, and take better care of our customers.”

Overall, the 2024 Technology Fast 500 companies achieved revenue growth ranging from 201% to 186,373% over the three-year time frame, with an average growth rate of 2,097% and median growth rate of 458%.

“For 30 years, we’ve been celebrating companies that are actively driving innovation. The software industry continues to be a beacon of growth, and the fintech industry made a strong showing on this year’s list, surpassing life sciences for the first time,” said Steve Fineberg, vice chair, U.S. technology sector leader, Deloitte. “Significantly, we also saw a breakthrough in performance of private companies, with the highest number of private companies named to the list in our program’s history. This year’s winners have shown they have the vision and expertise to continue to perform at a high level, and that deserves to be celebrated.”

For more information, visit www.workiz.com.

About Workiz
Workiz is a leading field service management platform designed to help service professionals streamline their operations, improve customer satisfaction, and grow their businesses. With innovative tools like the AI assistant Genius, Workiz is committed to bringing cutting-edge technology to the field service industry. To learn more about Workiz, visit the website: www.workiz.com.

About the 2024 Deloitte Technology Fast 500
Now in its 30th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

MEDIA CONTACT:
Heather Ripley
Ripley PR
(865) 977-1973
hripley@ripleypr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/workiz-recognized-as-one-of-north-americas-fastest-growing-companies-on-the-2024-deloitte-technology-fast-500-302311744.html

SOURCE Workiz

Continue Reading

Technology

Report Reveals 70% of Medtechs Use Manual Processes for Managing Content and Claims

Published

on

By

Reducing content approvals from more than four weeks and automating claims are key opportunities to drive speed to market

PLEASANTON, Calif., Nov. 21, 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced findings from the 2024 Veeva MedTech Commercial Benchmark survey revealing nearly 70% of medtech organizations rely on manual processes and homegrown applications to manage commercial content and claims. Without a purpose-built content management system, medtech commercial teams face go-to-market delays and growing compliance risk.

Despite the importance of connecting claims, evidence, and promotional materials, only 15% of organizations have streamlined processes with a central data repository where claims are directly linked to substantiation. The data shows there is significant opportunity for improvement across commercial content and claims management to gain visibility and speed.

The benchmark survey of over 130 commercial medtech leaders found that:

Content personalization is a growing focus. More than 80% are pursuing strategies to tailor and specify messaging. Achieving compliant personalization at scale without the right systems remains a challenge amid strict regulatory requirements.

Digital asset management (DAM) not yet in place for true omnichannel. Nearly 40% of organizations report not having a DAM system in place, limiting the management of personalizing content. Among those with a DAM, only 31% report having it accessible across marketing.

Prolonged approval times result in missed opportunities. 60% of medtech companies using manual processes or homegrown solutions experience approvals taking more than four weeks. Marketing assets undergo an average of three to five rounds of reviews which can delay campaign launches, affecting product awareness and sales momentum.

AI and automation of content continues to influence medtech. 45% of medtech organizations feel the most significant area AI can contribute is content creation.

“As the demand grows for more personalized promotional materials, medtech companies face scale and compliance challenges to adhere to regulatory standards and accurately reflect product efficacy and safety,” said Jeff Gorski, senior director of commercial content strategy, Veeva MedTech. “This report shows that nearly every medtech organization has an opportunity to improve content and claims management processes for greater speed to market, compliance, and efficiency.”

The 2024 Veeva MedTech Commercial Benchmark survey examines the current processes, challenges, and future opportunities for improvement in managing promotional content and claims.

Additional Information
For more on Veeva Vault PromoMats for MedTech, visit: veeva.com/medtech/PromoMats
Connect with Veeva on LinkedIn: https://www.linkedin.com/showcase/veeva-medtech/

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Alison Borris
Veeva Systems
925-226-8821
alison.borris@veeva.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/report-reveals-70-of-medtechs-use-manual-processes-for-managing-content-and-claims-302312460.html

SOURCE Veeva Systems

Continue Reading

Trending